Preclinical Evaluation in Animals for the Efficacy, Dosimetry, and Safety of [68Ga]Ga/[177Lu]Lu-TVS-PSMA Radioligands, and First-in-Human Study of [68Ga]Ga-TVS-PSMA-1
Bioconjugate Chemistry · 19.08.2026 · 37 (8) · 1633-1642
DOI: 10.1021/acs.bioconjchem.6c00211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, online erschienen am 17.07.2026. Verfasst von Yuduo Wan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical Un…. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Lutetium, Radiopharmaceuticals, Radioisotopes. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Luzhou Science and Technology Program, Sichuan Province Science and Technology Support Program, Gansu Isotope Laboratory.
Abstract (Originalsprache)
To improve the theranostic efficacy of PSMA-targeted radiopharmaceuticals on patients with medium-to-low PSMA expression, we radiolabeled a series of novel designed PSMA-targeting dimer agents to improve tumor imaging and treatment outcomes under challenging conditions. All agents were successfully radiolabeled with 68Ga in moderate decay-corrected labeling yield and high radiochemical purity. Among them, [68Ga]Ga-TVS-PSMA-1 exhibited high tumor uptake in both LNCaP and 22RV1 models. [177Lu]Lu-TVS-PSMA-1 demonstrated significantly improved treatment efficacy with a lower dose and good safety profile compared with [177Lu]Lu-PSMA-617. A first-in-human [68Ga]Ga-TVS-PSMA-1 PET/CT scan was performed in a 66-year-old male prostate cancer patient. Two metastatic lesions in the lumbar vertebrae were clearly visualized, and the primary tumor exhibited an SUVmax of 30.3. The [68Ga]Ga-TVS-PSMA-1 showed lower salivary gland uptake compared with previously reported values for [68Ga]Ga-PSMA-11; however, confirmation in larger patient cohorts is required. This study demonstrates that the dimer agent TVS-PSMA-1 holds great potential as a next-generation theranostic agent for prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping St, Jiangyang District, Luzhou, Sichuan646000…
- School of Pharmacy, Southwest Medical University, Luzhou, Sichuan646000, China.
- Department of Radiology, Lineberger Comprehensive Cancer Center, and Biomedical Research Imaging Center, University of North Carolina, Chapel Hill, North Carolina27599, United States.
Förderung
- Luzhou Science and Technology Program
- Sichuan Province Science and Technology Support Program
- Gansu Isotope Laboratory
Zitieren
APA
Wan, Y., Wang, Y., Feng, W., Yang, L., Sun, Q., Chen, H., Liu, Y., Zhu, Y., Zhang, H., Ding, H., Li, Z., & Wang, L. (2026). Preclinical Evaluation in Animals for the Efficacy, Dosimetry, and Safety of [68Ga]Ga/[177Lu]Lu-TVS-PSMA Radioligands, and First-in-Human Study of [68Ga]Ga-TVS-PSMA-1. Bioconjugate Chemistry, 37(8), 1633-1642. https://doi.org/10.1021/acs.bioconjchem.6c00211
Vancouver
Wan Y, Wang Y, Feng W, Yang L, Sun Q, Chen H, et al. Preclinical Evaluation in Animals for the Efficacy, Dosimetry, and Safety of [68Ga]Ga/[177Lu]Lu-TVS-PSMA Radioligands, and First-in-Human Study of [68Ga]Ga-TVS-PSMA-1. Bioconjugate Chemistry. 2026;37(8):1633-1642. doi:10.1021/acs.bioconjchem.6c00211
BibTeX
@article{Wan2026,
author = {Wan, Yuduo and Wang, Yang and Feng, Wanlu and Yang, Liping and Sun, Qinghong and Chen, Huanyu and Liu, Ya and Zhu, Yan and Zhang, He and Ding, Haoyuan and Li, Zibo and Wang, Li},
title = {Preclinical Evaluation in Animals for the Efficacy, Dosimetry, and Safety of [68Ga]Ga/[177Lu]Lu-TVS-PSMA Radioligands, and First-in-Human Study of [68Ga]Ga-TVS-PSMA-1},
journal = {Bioconjugate Chemistry},
year = {2026},
volume = {37},
number = {8},
pages = {1633--1642},
doi = {10.1021/acs.bioconjchem.6c00211}
}
EUVIMED